Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Long-Term Investments (2017 - 2025)

Historic Long-Term Investments for Protagonist Therapeutics (PTGX) over the last 7 years, with Q3 2025 value amounting to $102.7 million.

  • Protagonist Therapeutics' Long-Term Investments fell 1038.13% to $102.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year decrease of 1038.13%. This contributed to the annual value of $140.3 million for FY2024, which is N/A changed from last year.
  • As of Q3 2025, Protagonist Therapeutics' Long-Term Investments stood at $102.7 million, which was down 1038.13% from $102.5 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Long-Term Investments registered a high of $140.3 million during Q4 2024, and its lowest value of $2.0 million during Q3 2023.
  • In the last 4 years, Protagonist Therapeutics' Long-Term Investments had a median value of $70.4 million in 2021 and averaged $68.8 million.
  • Per our database at Business Quant, Protagonist Therapeutics' Long-Term Investments soared by 563000.0% in 2024 and then crashed by 1038.13% in 2025.
  • Protagonist Therapeutics' Long-Term Investments (Quarter) stood at $38.2 million in 2021, then plummeted by 94.76% to $2.0 million in 2023, then soared by 6915.0% to $140.3 million in 2024, then fell by 26.8% to $102.7 million in 2025.
  • Its Long-Term Investments stands at $102.7 million for Q3 2025, versus $102.5 million for Q2 2025 and $123.5 million for Q1 2025.